| |
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
Today’s Big NewsMar 24, 2025 |
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| By Gabrielle Masson President Donald Trump’s Department of Government Efficiency has again revised savings estimates tied to federal site closures, nearly halving the unit’s initial forecast. The agency has also removed 91 federal sites previously listed on its “wall of receipts” for planned lease cancellations, including three FDA sites. |
|
|
|
By Conor Hale After outlining plans nearly one year ago to take 23andMe private—and submitting multiple offers—co-founder and CEO Anne Wojcicki will now resign as chief of the genetic testing company as it files for Chapter 11 bankruptcy and instead pursues a court-managed sale. |
By Fraiser Kansteiner Biogen on Monday said it signed a 15-year lease for a building at Cambridge’s Kendall Common that the company plans to use as its new global headquarters. The Big Biotech says it will move its current Cambridge-based employees to the site at the time of its expected opening in 2028, which will coincide with Biogen’s 50th anniversary. |
By Andrea Park As the college basketball March Madness tournament gets underway, so too does Fierce Pharma Marketing’s annual #FierceMadness competition. |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now.
|
|
By Angus Liu Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. |
By Nick Paul Taylor AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend” itself against the claims. |
By James Waldron The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon. |
By Kevin Dunleavy International vaccine partnership Gavi has discontinued a COVID vaccine advance purchase agreement with Clover Biopharmaceuticals of China and is asking for repayment of $224 million. |
By Conor Hale Abbott's approach will use high-energy sound pressure waves to crack obstructive deposits within the blood vessel before the placement of a stent. |
By Gabrielle Masson Before Jazz Pharmaceuticals inked a $935 million deal for Chimerix, the biotech had been in talks with six other pharmas and one biotech about several different potential offers. |
By Nick Paul Taylor Harmony Biosciences has named Adam Zaeske its chief commercial officer, luring the Takeda veteran back from Europe to lead a push to turn Wakix into a blockbuster and prepare to launch other drugs. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the potential impacts of this year's sizable patent cliff on the pharma industry at large. |
|
|---|
|
|
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
